Arancioglu S, Ulker OC, Karakaya A (2015) Utilization of the ex vivo LLNA: BrdU-ELISA to distinguish the sensitizers from irritants in respect of 3 end points—lymphocyte proliferation, ear swelling, and cytokine profiles. Int J Toxicol 34(1):24–30
Assessment USCOoT (1991) Identifying and controlling immunotoxic substances: background paper. US Government Printing Office
Bindea G, Mlecnik B, Tosolini M et al (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. https://doi.org/10.1016/j.immuni.2013.10.003
Bosshart H, Heinzelmann M (2016) THP-1 cells as a model for human monocytes. Ann Transl Med 4(21):438. https://doi.org/10.21037/atm.2016.08.53
Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 29(5):435–466. https://doi.org/10.1177/1091581810374654
Carfi M, Gennari A, Malerba I et al (2007) In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 229(1–2):11–22
Cassetta L, Fragkogianni S, Sims AH et al (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35(4):588-602.e10. https://doi.org/10.1016/j.ccell.2019.02.009
Chang KT, Lin HY, Kuo CH, Hung CH (2016) Tacrolimus suppresses atopic dermatitis-associated cytokines and chemokines in monocytes. J Microbiol Immunol Infect 49(3):409–416. https://doi.org/10.1016/j.jmii.2014.07.006
Chen L, Liu J, Zhang Y et al (2018) The toxicity of silica nanoparticles to the immune system. Nanomedicine 13(15):1939–1962
Collinge M, Ball DJ, Bowman CJ, Nilson AL, Radi ZA, Vogel WM (2018) Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats–comparison of juvenile and adult responses. Regul Toxicol Pharmacol 94:306–322
Corsini E, Roggen EL (2009) Immunotoxicology: opportunities for non-animal test development. Altern Lab Anim 37(4):387–397. https://doi.org/10.1177/026119290903700409
Crotty S, Maag D, Arnold JJ et al (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6(12):1375–1379. https://doi.org/10.1038/82191
Descotes J (2004) Importance of immunotoxicity in safety assessment: a medical toxicologist’s perspective. Toxicol Lett 149(1–3):103–108. https://doi.org/10.1016/j.toxlet.2003.12.024
Diehl R, Ferrara F, Müller C et al (2017) Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 14(2):146–179
Diepgen TL, Ofenloch RF, Bruze M et al (2016) Prevalence of contact allergy in the general population in different European regions. Br J Dermatol 174(2):319–329. https://doi.org/10.1111/bjd.14167
Fielder RJ (1995) Risk assessment of chemicals: general principles (and how these relate to immunotoxicity). Hum Exp Toxicol 14(1):150. https://doi.org/10.1177/096032719501400139
Furst DE, Clements PJ, Hillis S et al (1989) Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32(5):584–593
Galbiati V, Mitjans M, Corsini E (2010) Present and future of in vitro immunotoxicology in drug development. J Immunotoxicol 7(4):255–267. https://doi.org/10.3109/1547691X.2010.509848
Gennari A, Ban M, Braun A et al (2005) The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J Immunotoxicol 2(2):61–83. https://doi.org/10.1080/15476910590965832
Germolec DR (2004) Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance. Toxicol Lett 149(1–3):109–114. https://doi.org/10.1016/j.toxlet.2003.12.025
Germolec D, Luebke R, Rooney A, Shipkowski K, Vandebriel R, van Loveren H (2017) Immunotoxicology: a brief history, current status and strategies for future immunotoxicity assessment. Curr Opin Toxicol 5:55–59. https://doi.org/10.1016/j.cotox.2017.08.002
Hartung T, Corsini E (2013) Immunotoxicology: challenges in the 21st century and in vitro opportunities. Altex 30(4):411–426. https://doi.org/10.14573/altex.2013.4.411
Johansson H, Lindstedt M, Albrekt AS, Borrebaeck CA (2011) A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 12:399. https://doi.org/10.1186/1471-2164-12-399
Johansson H, Albrekt A-S, Borrebaeck CA, Lindstedt M (2013) The GARD assay for assessment of chemical skin sensitizers. Toxicol in Vitro 27(3):1163–1169
Kimura Y, Fujimura C, Ito Y, Takahashi T, Aiba S (2014) Evaluation of the multi-immunotox assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. Toxicol in Vitro 28(5):759–768. https://doi.org/10.1016/j.tiv.2014.02.013
Kimura Y, Fujimura C, Ito Y, Takahashi T, Terui H, Aiba S (2018) Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the multi-immunotox assay and the IL-8 luc assay. Arch Toxicol 92(6):2043–2054. https://doi.org/10.1007/s00204-018-2199-7
Kimura Y, Terui H, Fujimura C, Amagai R, Takahashi T, Aiba S (2021) Optimization of the IL-2 Luc assay for immunosuppressive drugs: a novel in vitro immunotoxicity test with high sensitivity and predictivity. Arch Toxicol 95(8):2755–2768
Koller L (1973) Immunosuppression produced by lead, cadmium, and mercury. Am J Vet Res 34(11):1457–1458
Langezaal I, Hoffmann S, Hartung T, Coecke S (2002) Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release. Altern Lab Anim 30(6):581–595
Lankveld DP, Van Loveren H, Baken KA, Vandebriel RJ (2010) In vitro testing for direct immunotoxicity: state of the art. Methods Mol Biol 598:401–423. https://doi.org/10.1007/978-1-60761-401-2_26
Losa Garcia JE, Mateos Rodriguez F, Jimenez Lopez A et al (1998) Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Respir Med 92(5):722–728. https://doi.org/10.1016/s0954-6111(98)90002-6
Luster MI, Portier C, Paît DG et al (1992) Risk assessment in immunotoxicology: I. Sensitivity and predictability of immune tests. Toxicol Sci 18(2):200–210
Ma H, Lin J, Li L et al (2021) Formaldehyde reinforces pro-inflammatory responses of macrophages through induction of glycolysis. Chemosphere 282:131149. https://doi.org/10.1016/j.chemosphere.2021.131149
Madden JC, Enoch SJ, Paini A, Cronin MTD (2020) A review of in silico tools as alternatives to animal testing: principles, resources and applications. Altern Lab Anim 48(4):146–172. https://doi.org/10.1177/0261192920965977
Mendez D, Gaulton A, Bento AP et al (2019) ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 47(D1):D930–D940. https://doi.org/10.1093/nar/gky1075
Miossec P (1997) Cytokine-induced autoimmune disorders. Drug Saf 17(2):93–104. https://doi.org/10.2165/00002018-199717020-00002
Na YR, Kwon JW, Kim DY et al (2020) Protein kinase a catalytic subunit is a molecular switch that promotes the pro-tumoral function of macrophages. Cell Rep 31(6):107643. https://doi.org/10.1016/j.celrep.2020.107643
OECD (2018) Test no. 442E: In vitro skin sensitisation
Poppe D, Tiede I, Fritz G et al (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176(1):640–651
Sakaguchi H, Ashikaga T, Miyazawa M et al (2006) Development of an in vitro skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT). II. An inter-laboratory study of the h-CLAT. Toxicol in Vitro 20(5):774–784. https://doi.org/10.1016/j.tiv.2005.10.014
Schindler S, Hartung T, Human Pyrogen Test Study Group (2002) Comparison and validation of novel pyrogen tests based on the human fever reaction. Dev Biol (basel) 111:181–186
Sensitisation OS (2002) Local lymph node assay. OECD Paris 429:1–7
Shah A, Dobrovolskaia MA (2018) Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: therapeutic benefits, toxicity, mechanistic insights, and translational considerations. Nanomedicine 14(3):977–990
Sia IG, Paya CV (1998) Infectious complications following renal transplantation. Surg Clin North Am 78(1):95–112. https://doi.org/10.1016/s0039-6109(05)70637-x
Steele RW, Marmer DJ, Keeney RE (1980) Comparative in vitro imunotoxicology of acyclovir and other antiviral agents. Infect Immun 28(3):957–962
Stevenson H, Fauci A (1980) Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 39(3):391
留言 (0)